IVD PRODUCT | FOXCARD®

FOXCARD®

AR/CD8/FOXC1/DCLK1 antibody detection reagent (immunohistochemistry method)

Exclusive authorization: exclusive patented technology of the Affiliated Cancer Hospital of Fudan University
Guideline recommendation: “Guidelines and Standards for the Diagnosis and Treatment of Breast Cancer of the Chinese Anti-Cancer Association”
Innovative classification: Triple-negative breast cancer is further subdivided into different molecular types using four markers
Precision therapy: Provides guidance for the precision treatment of triple-negative breast cancer, with the ORR of patients with “no available drug” increasing by 3 times; the ORR of patients in the immunotherapy group reached 43.5%; the median PFS of patients in the advanced first-line group increased by 5.5 months
The antibody has good specificity and high staining intensity, which can greatly avoid false negatives and false positives, and assist pathologists in making accurate diagnoses.

PREFERRED POPULATION

CLINICAL VALUE

Early-stage TNBC patients: different classifications indicate differences among patients.
Patients with advanced TNBC: Multi-classification and multi-target assistance in clinical exploration of more personalized and precise treatment plans.

PRODUCT INFO

References

1.《免疫组织化学在乳腺病理中的应用共识（2022版）》

2. Liu YH et al. Oncotarget. 2016 Jan 12;7(2):1464-76.

3. Wang YL et al, Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9489-9498.

4. Liu H et al. Biomed Res Int. 2019 May 15:2019:1061979.

5. Jin X et al. Nature Genetics. 2023;55(10):1696-1708.

6. Rapoport BL et al. Cancers (Basel). 2022 May 20;14(10):2525.